Browsing by Autor "Alan Jobe"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item type: Item ,
    Addressing the long-term risks of administering antenatal steroids
    (Taylor & Francis, 2025) Sean W.D. Carter; Agnihotri Biswas; Hunna J. Watson; Hugh Ip; Erin L. Fee; K.H.W. Seah; Yusaku Kumagai; Zubair Amin; Mahesh Choolani; Alan Jobe
    Our assessment is that: i) Currently used, high dose ANS regimens can induce multi-system changes in the fetus that alter growth and development, potentially increasing long-term disease risk; and ii) relative risks likely increase proportionally to the magnitude and duration of steroid exposure, in late preterm and term ANS use, and in off-target treatments. A single course of ANS therapy to at risk women between 24- and 34-weeks' gestation is well justified. Efforts should be made to improve dosing and patient selection. At periviable gestations, the high immediate risk of serious disease or death justifies modest long-term risks. At late preterm and term gestations, where steroids do not provide notable survival or health benefits, supporting routine ANS use is more difficult.